Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial. This translated to an average loss of 50.3 lb (22.8 kg) with ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

The "head-to-head results demonstrated tirzepatide [Zepbound] led to greater weight reduction compared with semaglutide [Wegovy], providing further evidence to support tirzepatide as an effective ...

Researchers administered weekly injections — either a placebo or semaglutide — to 800 patients across 37 countries between 2021 and 2023. More than half of participants had Type 2 diabetes ...

For the study, researchers randomly assigned 751 participants with obesity but not Type 2 diabetes to take either tirzepatide, aka Zepbound, or semaglutide, aka Wegovy, weekly, for 72 weeks.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) over 72 weeks, while those who took semaglutide, or Wegovy, lost about 33 ...

How Does Semaglutide Work for Weight Loss? This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Ozempic. Wegovy. Rybelsus. What do these medications have in common? They all contain ...

The first head-to-head trial of two blockbuster weight-loss drugs has shown Mounjaro is more effective than rival Wegovy. Both drugs led to substantial weight loss, but Mounjaro's 20% weight ...